Phase I and pharmacokinetic study of hepsulfam (NSC 329680).

Hendricks, C B; Grochow, L B; Rowinsky, E K; Forastiere, A A; McGuire, W P; Ettinger, D S; Sartorius, S; Lubejko, B; Donehower, R C

Hendricks, C B; Grochow, L B; Rowinsky, E K; Forastiere, A A; McGuire, W P; Ettinger, D S; Sartorius, S; Lubejko, B; Donehower, R C.

Affiliation

Hendricks CB; Division of Pharmacology and Experimental Therapeutics, Johns Hopkins Oncology Center, Baltimore, Maryland 21205.

Cancer Res ; 51(21): 5781-5, 1991 Nov 01.

Article in En | MEDLINE | ID: mdl-1933848

Subject(s)

Antineoplastic Agents/toxicity; Neoplasms/drug therapy; Sulfonic Acids/toxicity; Adult; Drug Evaluation; Female; Humans; Leukopenia/chemically induced; Male; Metabolic Clearance Rate; Neutropenia/chemically induced; Sulfonic Acids/pharmacokinetics; Sulfonic Acids/therapeutic use; Thrombocytopenia/chemically induced

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Sulfonic Acids / Neoplasms / Antineoplastic Agents Limits: Adult / Female / Humans / Male Language: En Journal: Cancer Res Year: 1991 Type: Article

Search on Google

XML

PubMed Links